Triamcinolone acetonide 0.1% w/w is a potent synthetic fluorinated glucocorticoid (Group III) for topical use. It exerts anti-inflammatory, anti-pruritic, and vasoconstrictive effects by inhibiting multiple inflammatory mediators. It is a mainstay in Indian dermatology for managing steroid-responsive dermatoses, available in various formulations (cream, ointment, lotion). Its potency makes it suitable for short-term treatment of moderate to severe inflammatory skin conditions.
Adult: Apply a thin film to the affected area 2 to 3 times daily. Therapy should be limited to 2-4 weeks. For chronic conditions, use the lowest effective frequency (e.g., once daily or alternate days).
Note: 1. Wash and dry the affected area gently. 2. Apply a pea-sized amount (or a thin film) and rub in gently until absorbed. 3. Wash hands after application unless hands are the treatment site. 4. Do not apply on broken skin, around the eyes, or on mucous membranes. 5. Occlusive dressings should only be used under strict medical supervision for resistant lesions like psoriasis or lichenification.
Triamcinolone acetonide diffuses across cell membranes and binds with high affinity to cytoplasmic glucocorticoid receptors. The receptor-ligand complex translocates to the nucleus, where it modulates gene transcription. It induces the synthesis of anti-inflammatory proteins (e.g., lipocortin-1) and inhibits the synthesis of pro-inflammatory mediators.
Pregnancy: Pregnancy Category C (US FDA). Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Avoid large amounts, prolonged use, or use under occlusion. Animal studies show teratogenicity with systemic administration. There are no adequate and well-controlled studies in pregnant women.
Driving: No effect on driving ability.
| Other Topical Corticosteroids | Additive risk of local and systemic side effects. | Major |
| Topical Retinoids (Tretinoin, Adapalene) | May increase irritation and dryness. Sequential application is recommended. | Moderate |
| Topical Immunosuppressants (Tacrolimus, Pimecrolimus) | Theoretical increased risk of infection and malignancy. Usually not combined. | Moderate |
| Live Attenuated Vaccines (applied to treated area) | Potential for disseminated infection and reduced vaccine efficacy. | Major |